Tally Health is under new ownership. The biotechnology platform, which performs epigenetic age testing for consumers and tailors product and lifestyle recommendations for them, has been acquired by Infinite Epigenetics in a deal of undisclosed size. Infinite Epigenetics, and its subsidiary TruDiagnostic, will continue under the leadership of chief executive officer Dr. Matthew Dawson, while Tally’s CEO Melanie Goldey will stay on as well. Related Articles “Their business is predominantly [business-to-business]. They work with research organizations, academia, payers and providers, and they do have a small consumer business as well. But Tally is really meant to augment what they have built,” Goldey said. “We’re going to continue operating Tally from within Infinite Epigenetics, so our customers are not going to see any disruption or anything.…